Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

the trial is expected to take approximately fourteen months: two months for screening, three months for subject treatment and a further nine months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

Phase 2 Study of SB-509 to Evaluate Stem Cell Mobilization (SB-509-703)

Twenty subjects will be enrolled in the stem cell mobilization Phase 2 trial. Subjects will be randomized to one of four cohorts with 5 subjects in each cohort. Cohorts 1 and 2 will receive a single treatment of 30 mg into one leg or 60 mg (30 mg in each leg) of SB-509, respectively, by intramuscular (IM) injection on Day 0. Cohort 3 will receive a single treatment of an equal volume of placebo by IM injection into a lower limb on Day 0. Cohort 4 will receive two treatments of 60 mg of SB-509 (30 mg in each leg) by IM injection (Day 0 and 90). Subjects will receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

Peripheral blood samples taken before and at various times post-treatment with SB-509 will be assayed and the numbers of circulating stem cells will be assessed using stem cell-specific enzymatic activity (aldehyde dehydrogenase staining), culture-based assays, as well as assays of cell surface expression of stem cell-specific markers.

The signs and symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will also be evaluated based on neurological examination data (NIS-LL), electrophysiological testing data, subject neurological questionnaire, and subject pain assessment (VASPI). Specifically, investigators will use the following tests: QST with the Vibratron II instrument, to assess the threshold of detection of vibration and electrophysiological testing. A total neuropathy composite score (TNS) will also be computed to evaluate changes in nerve health.
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans believe ... is a serious public health and safety issue in ... a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse ... with this very serious health situation facing our country," ...
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
(Date:8/22/2014)... 2014 Until now, those with leg or ... walkers to keep mobile. Thanks to an inventor from Suffolk, ... effective. , He developed a prototype for the patent-pending SUPPORT ... or foot but provide comfort and reduce pain for those ... it is also convenient and easy to install on the ...
(Date:8/22/2014)... 265,000 Danes are acutely admitted to medical departments with ... and Aarhus University Hospital now shows that many of ... are sent home again without receiving a diagnosis of ... "Naturally, there is no need for a diagnosis if ... a serious illness. So some patients will always be ...
(Date:8/22/2014)... intolerance. However, these are two entirely different mechanisms that ... not digest lactose properly because they lack an enzyme ... much more dangerous cow milk allergy, however, the body,s ... antibodies. , According to statistics, about two to three ... milk allergy. Less adults are diagnosed with the disease. ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ALS ... the ALS Center at Allegheny Health Network ... Center, based at Allegheny General Hospital (AGH), is the ... the ALS Association for meeting the highest levels of ... amyotrophic lateral sclerosis (ALS), often referred to as Lou ...
(Date:8/22/2014)... 21, 2014 (HealthDay News) -- The air in American ... Protection Agency reported Thursday. Significant progress has been ... air in recent decades, the agency said in a ... nearly 60 percent reduction in mercury from human sources ... benzene, and an 84 percent fall in lead, which ...
Breaking Medicine News(10 mins):Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Many patients are discharged without a diagnosis 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Sept. 14 The following is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen some ... politicians who want to,return those funds received from me, please return them in the form of ... ... Medical Foundation ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) management will be ... 43rd Annual Meeting of the European,Association for the Study ... a.m. PT / 1:30 p.m. CET local time in ... and recordings will be made,available following the event. The ...
... defects, U.S. experts say , , FRIDAY, Sept. 14 (HealthDay News) ... women since the federal government mandated folate fortification to prevent ... is enough -- or too much. , A new study ... finds that the number of women of childbearing age who ...
... Most people looking for tax advice,usually go to ... right? Here,s more on a new report that shows ... are actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, ...
... Blue Cross and Blue,Shield Association (BCBSA) convened a ... D.C., to discuss how insurers, doctors and hospitals,are ... safety.,Representatives from the Premier Inc. healthcare alliance, Duke ... Alabama, and WellPoint, Inc.,participated in the event. ...
... between the two protective treatments , FRIDAY, Sept. 14 (HealthDay ... a pill called dabigatran etexilate (DE) is just as effective ... blood clots after total hip replacement surgery. , As reported ... study included almost 3,500 hip replacement patients who received either ...
Cached Medicine News:Health News:Women's Folic Acid Levels Improving 2Health News:Women's Folic Acid Levels Improving 3Health News:Women's Folic Acid Levels Improving 4Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 2Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 3Health News:Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 4Health News:Pill Equals Injection in Preventing Clots After Hip Replacement 2
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: